Real-World Patterns of Peri-Procedural Antiplatelet Therapy and Concomitant Verapamil Use During Transradial Percutaneous Coronary Intervention
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Background Antiplatelet therapy is routinely used during transradial percutaneous coronary intervention (PCI). Verapamil is commonly administered peri-procedurally to prevent radial artery spasm; however, real-world data describing antiplatelet therapy patterns and concomitant verapamil exposure during PCI remain limited. This study aimed to characterize peri-procedural medication exposure patterns, with particular focus on the co-occurrence of ticagrelor and verapamil. Methods This single-center retrospective study analyzed PCI encounters between 2024 and 2025 using routinely collected hospital data. Peri-procedural antiplatelet therapy was classified by P2Y12 inhibitor use (ticagrelor, clopidogrel, or none). Verapamil and other concomitant medications were identified from medication records using a predefined keyword dictionary. The primary outcome was the prevalence of concomitant ticagrelor and verapamil exposure. Results A total of 204 PCI cases were included. Clopidogrel was the most frequently used P2Y12 inhibitor (104/204, 51.0%), followed by ticagrelor (68/204, 33.3%) and no P2Y12 inhibitor (32/204, 15.7%). Verapamil was administered in 98.5% (201/204) of cases. The co-occurrence of ticagrelor and verapamil was observed in 32.4% (66/204) of all cases and 97.1% (66/68) of ticagrelor users. Patients receiving ticagrelor were younger (median 61.0 vs 68.5 years) and more often male (85.3% vs 66.3%) compared with clopidogrel users. The proportion of ticagrelor use declined from 43.2% in 2024 to 27.7% in 2025. Conclusions In this real-world cohort of transradial PCI cases, verapamil was near-universally administered peri-procedurally, and concomitant exposure with ticagrelor was common. These findings provide empirical evidence that ticagrelor–verapamil co-exposure occurs frequently in routine practice and may inform the design of future pharmacokinetic or outcome-focused studies.
Fields of Study & Subjects
Antiplatelet Therapy and Cardiovascular Diseases
Coronary Interventions and Diagnostics
Vascular Procedures and Complications
Publication details
- Journal / source
- Research Square
- Publication date
- 28 March 2026
- Language
- EN
- Document type
- Preprint